Showing results (81-90 of 196) with videos related to
Sort By:
Pageof 20
The Journal of Nutrition|March 15, 2013
Trans fatty acid intake is associated with increased risk and n3 fatty acid intake with reduced risk of non-hodgkin lymphomaBridget Charbonneau, Helen M O'Connor, Alice H Wang, et al.British Journal of Haematology|July 27, 2001
A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasiaR A Mesa, A Tefferi, M A Elliott, et al.Cancer Genetics and Cytogenetics|April 25, 2006
Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemiaKimberly J Stockero, Stephanie R Fink, Stephanie A Smoley, et al.Haematologica|August 6, 2013
Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomesSameer A Parikh, Kari G Rabe, Neil E Kay, et al.Annals of Epidemiology|November 14, 2012
The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of genderJennifer L Kelly, Zachary S Fredericksen, Mark Liebow, et al.Blood|November 19, 2008
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcomeTait D Shanafelt, Neil E Kay, Greg Jenkins, et al.Vaccine|January 19, 2021
The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)Jennifer A Whitaker, Sameer A Parikh, Tait D Shanafelt, et al.Cancer|August 8, 2013
Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)Tait Shanafelt, Mark C Lanasa, Timothy G Call, et al.Cancer|June 26, 2010
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemiaTait D Shanafelt, Kari G Rabe, Neil E Kay, et al.Journal of Oncology Practice|March 26, 2015
Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levelsTait D Shanafelt, Bijan J Borah, Heidi D Finnes, et al.Pageof 20